Analysts give the thumbs up to Bristol-Myers Squibb's (BMY -0.25%) and AstraZeneca's (AZN -1.2%)...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Analysts give the thumbs up to Bristol-Myers Squibb's (BMY -0.25%) and AstraZeneca's (AZN -1.2%) purchase of Amylin (AMLN). "The acquisition is a good strategic fit...with a sound financial basis and tangible economic benefits," says Deutsche Bank. UBS, Wells Fargo and Leerink Swann are also positive.